Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Recommendation of “Buy” from Analysts

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) have been assigned a consensus recommendation of “Buy” from the eight research firms that are presently covering the firm, Marketbeat reports. Eight investment analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $6.63.

Several brokerages have recently issued reports on TSHA. Needham & Company LLC reiterated a “buy” rating and issued a $6.00 price objective on shares of Taysha Gene Therapies in a research note on Thursday, February 27th. Cantor Fitzgerald restated an “overweight” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Canaccord Genuity Group boosted their target price on Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a “buy” rating in a research note on Friday, November 15th. JMP Securities restated a “market outperform” rating and set a $5.00 target price on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Finally, Chardan Capital restated a “buy” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research note on Wednesday, February 26th.

Institutional Investors Weigh In On Taysha Gene Therapies

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Squarepoint Ops LLC lifted its stake in Taysha Gene Therapies by 105.4% in the fourth quarter. Squarepoint Ops LLC now owns 211,842 shares of the company’s stock valued at $366,000 after buying an additional 108,719 shares during the last quarter. Rafferty Asset Management LLC purchased a new stake in Taysha Gene Therapies in the fourth quarter valued at approximately $436,000. ProShare Advisors LLC lifted its stake in Taysha Gene Therapies by 32.3% in the fourth quarter. ProShare Advisors LLC now owns 59,076 shares of the company’s stock valued at $102,000 after buying an additional 14,418 shares during the last quarter. Octagon Capital Advisors LP lifted its stake in Taysha Gene Therapies by 128.6% in the fourth quarter. Octagon Capital Advisors LP now owns 10,450,000 shares of the company’s stock valued at $18,078,000 after buying an additional 5,877,778 shares during the last quarter. Finally, Millennium Management LLC purchased a new stake in Taysha Gene Therapies in the fourth quarter valued at approximately $262,000. Hedge funds and other institutional investors own 77.70% of the company’s stock.

Taysha Gene Therapies Stock Performance

Shares of TSHA opened at $1.72 on Tuesday. The stock has a 50-day simple moving average of $1.66 and a 200-day simple moving average of $1.95. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.51 and a current ratio of 5.51. The stock has a market capitalization of $352.60 million, a PE ratio of 2.73 and a beta of 0.91. Taysha Gene Therapies has a 1 year low of $1.19 and a 1 year high of $4.32.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.01. The business had revenue of $2.02 million during the quarter, compared to analysts’ expectations of $2.05 million. Taysha Gene Therapies had a negative return on equity of 106.36% and a negative net margin of 229.67%. On average, analysts predict that Taysha Gene Therapies will post -0.35 earnings per share for the current fiscal year.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.